State Street Corp Increases Position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

State Street Corp grew its position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 10.2% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,331,433 shares of the biopharmaceutical company's stock after purchasing an additional 216,484 shares during the quarter. State Street Corp owned approximately 4.09% of Agios Pharmaceuticals worth $103,586,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Erste Asset Management GmbH bought a new position in Agios Pharmaceuticals in the 3rd quarter worth $97,199,000. Caligan Partners LP boosted its stake in shares of Agios Pharmaceuticals by 12.6% in the third quarter. Caligan Partners LP now owns 579,717 shares of the biopharmaceutical company's stock worth $25,757,000 after acquiring an additional 65,006 shares during the period. Verition Fund Management LLC purchased a new stake in shares of Agios Pharmaceuticals during the third quarter worth about $315,000. Vestal Point Capital LP purchased a new stake in shares of Agios Pharmaceuticals during the third quarter worth about $33,767,000. Finally, Summit Partners Public Asset Management LLC purchased a new position in Agios Pharmaceuticals in the 3rd quarter worth approximately $4,520,000.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on AGIO. Raymond James reaffirmed an "outperform" rating and set a $51.00 price objective on shares of Agios Pharmaceuticals in a report on Thursday, October 10th. Leerink Partners cut shares of Agios Pharmaceuticals from an "outperform" rating to a "market perform" rating and cut their target price for the company from $60.00 to $56.00 in a research note on Friday, September 27th. StockNews.com upgraded shares of Agios Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Saturday, November 9th. Scotiabank increased their price objective on shares of Agios Pharmaceuticals from $53.00 to $75.00 and gave the company a "sector outperform" rating in a report on Monday, December 9th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Agios Pharmaceuticals in a report on Friday, September 20th. Five equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Hold" and a consensus target price of $56.33.

Insider Buying and Selling

In other news, CFO Cecilia Jones sold 2,542 shares of Agios Pharmaceuticals stock in a transaction on Thursday, September 26th. The stock was sold at an average price of $49.03, for a total transaction of $124,634.26. Following the completion of the sale, the chief financial officer now directly owns 20,158 shares in the company, valued at approximately $988,346.74. This trade represents a 11.20 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 4.93% of the stock is currently owned by corporate insiders.

Agios Pharmaceuticals Stock Up 9.6 %

AGIO traded up $3.72 on Monday, hitting $42.69. The company had a trading volume of 1,451,998 shares, compared to its average volume of 720,508. The company has a market cap of $2.43 billion, a PE ratio of 3.76 and a beta of 0.80. The business's fifty day simple moving average is $50.06 and its 200 day simple moving average is $46.80. Agios Pharmaceuticals, Inc. has a 12-month low of $20.96 and a 12-month high of $62.58.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.